Evidence map›Paper›PMID 38947169›Full record

ArticlePulmonary circulation2024

Treatment and management of chronic thromboembolic pulmonary hypertension (CTEPH): A global cross-sectional scientific survey (CLARITY).

Nika Skoro-Sajer, Karen Sheares, Paul Forfia, Gustavo A Heresi, Mitja Jevnikar, Grzegorz Kopeć, Olga Moiseeva, Mario Terra-Filho, Helen Whitford, Zhenguo Zhai and 5 more

Abstract read
In one paragraph

Article in Pulmonary circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nika Skoro-SajerDivision of Cardiology, Department of Internal Medicine II Medical University of Vienna Vienna Austria.
Karen ShearesRoyal Papworth Hospital Cambridge UK.
Paul ForfiaTemple University Hospital Philadelphia Pennsylvania USA.
Gustavo A HeresiCleveland Clinic Cleveland Ohio USA.
Mitja JevnikarHôpital de Bicêtre Le Kremlin-Bicêtre France.
Grzegorz KopećPulmonary Circulation Center Jagiellonian University Medical College, John Paul II Hospital in Krakow Krakow Poland.
Olga MoiseevaAlmazov National Medical Research Center St. Petersburg Russia.
Mario Terra-FilhoPulmonary Division, Heart Institute (Incor) University of Sao Paulo Sao Paulo Brazil.
Helen WhitfordThe Alfred Hospital Melbourne Australia.
Zhenguo ZhaiState Key Laboratory of Respiratory Health and Multimorbidity, Department of Pulmonary and Critical Care Medicine Center of Respiratory Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Diseases Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing China Beijing China.ORCID 0000-0002-7096-8792
Amélie BeaudetActelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, Global Market Access Allschwil Switzerland.
Virginie GressinActelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, Global Medical Affairs Allschwil Switzerland.
Catherina MeijerMonitor Deloitte Zaventem Belgium.ORCID 0000-0002-8487-3858
Yan Zhi TanMonitor Deloitte Zaventem Belgium.
Kohtaro AbeKyushu University Hospital Fukuoka Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) over the past decade changed the disease landscape, yet global insight on clinical practices remains limited. The CTEPH global cross-sectional scientific survey (CLARITY) aimed to gather information on the current diagnosis, treatment, and management of CTEPH and to identify unmet medical needs. This paper focuses on the treatment and management of CTEPH patients. The survey was circulated to hospital-based medical specialists through Scientific Societies and other medical organizations from September 2021 to May 2022. The majority of the 212 respondents involved in the treatment of CTEPH were from centers performing up to 50 pulmonary endarterectomy (PEA) and/or balloon pulmonary angioplasty (BPA) procedures per year. Variation was observed in the reported proportion of patients deemed eligible for PEA/BPA, as well as those that underwent the procedures, including multimodal treatment and subsequent follow-up practices. Prescription of pulmonary arterial hypertension-specific therapy was reported for a variable proportion of patients in the preoperative setting and in most nonoperable patients. Reported use of vitamin K antagonists and direct oral anticoagulants was similar (86% vs. 82%) but driven by different factors. This study presents heterogeneity in treatment approaches for CTEPH, which may be attributed to center-specific experience and region-specific barriers to care, highlighting the need for new clinical and cohort studies, comprehensive clinical guidelines, and continued education.

Indexed as

balloon pulmonary angioplastychronic thromboembolic pulmonary hypertensionclinical practicemedical therapypulmonary endarterectomy

Identifiers

PMID38947169
PMCPMC11214874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.